A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

NCT01706783 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions

DRUG: somapacitan
DRUG: Norditropin NordiFlex®

Sponsor

Novo Nordisk A/S